One year ago and just before the global rise of the pandemic, DiaSys has launched the CE-marked reagent Procalcitonin FS for sepsis management. The particle enhanced immunoturbidimetric assay enables precise determination of serum and plasma levels of procalcitonin on clinical chemistry analyzers.
Milestones besides the pandemic:
In addition to the 113 million SARS-CoV-2 infections and 2.5 million COVID-related deaths during the last year, sepsis remains a major global health threat. With nearly 50 million annual cases, sepsis causes 11 million deaths and is responsible to nearly one fifth of all global deaths. (3)
As Procalcitonin FS can be reliably performed on various clinical chemistry analyzers, we are looking forward to continue our success and provide Procalcitonin FS for sepsis management wherever it is needed.
- Dupuy, A. M. et al. Bioanalytical Performance of a New Particle-Enhanced Method for Measuring Procalcitonin. Diagnostics 10, 461 (2020).
- Reference Institute for Bioanalytics. Surveys PCT 2020. www.rfb.bio/cgi/surveys (2021).
- Rudd, K. E. et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. The Lancet 395, 200–211 (2020).